Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CTSO Cytosorbents Corp
- Stocks
- Healthcare
- NASDAQ: CTSO
Price (delayed)
$0.8402
Market cap
$52.61M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.28
Enterprise value
$66M
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the
Highlights
The quick ratio has soared by 69% YoY and by 22% QoQ
CTSO's EPS has soared by 53% YoY and by 26% from the previous quarter
The equity is up by 31% since the previous quarter but it has declined by 23% year-on-year
Cytosorbents's revenue has increased by 13% YoY but it has decreased by 3% QoQ
The debt has surged by 54% year-on-year
The gross margin is down by 6% YoY
Key stats
What are the main financial stats of CTSO
Market
Valuations
Earnings
Shares outstanding
62.61M
Market cap
$52.61M
Enterprise value
$66M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.61
Price to sales (P/S)
1.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.91
Revenue
$34.54M
Gross profit
$24.76M
Operating income
-$15.75M
Net income
-$15.84M
EBIT
-$15.53M
EBITDA
-$13.83M
Free cash flow
-$13.3M
Per share
Balance sheet
Liquidity
EPS
-$0.28
EPS diluted
-$0.28
Free cash flow per share
-$0.22
Book value per share
$0.23
Revenue per share
$0.57
TBVPS
$0.84
Total assets
$50.78M
Total liabilities
$36.24M
Debt
$26.5M
Equity
$14.54M
Working capital
$15.68M
Debt to equity
1.82
Current ratio
2.61
Quick ratio
2.13
Net debt/EBITDA
-0.97
Margins
Efficiency
Dividend
EBITDA margin
-40%
Gross margin
71.7%
Net margin
-45.9%
Operating margin
-45.6%
Return on assets
-31.8%
Return on equity
-114.4%
Return on invested capital
-28.7%
Return on capital employed
-37.8%
Return on sales
-45%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTSO stock price
How has the Cytosorbents stock price performed over time
Intraday
-1.16%
1 week
-3.43%
1 month
-18.43%
1 year
-14.21%
YTD
-7.67%
QTD
-15.98%
Financial performance
How have Cytosorbents's revenue and profit performed over time
Revenue
$34.54M
Gross profit
$24.76M
Operating income
-$15.75M
Net income
-$15.84M
Gross margin
71.7%
Net margin
-45.9%
Cytosorbents's operating margin has surged by 51% YoY and by 3.4% QoQ
The net margin has increased by 50% year-on-year and by 21% since the previous quarter
CTSO's operating income is up by 45% year-on-year and by 6% since the previous quarter
CTSO's net income is up by 43% year-on-year and by 24% since the previous quarter
Price vs fundamentals
How does CTSO's price correlate with its fundamentals
Growth
What is Cytosorbents's growth rate over time
Valuation
What is Cytosorbents stock price valuation
P/E
N/A
P/B
3.61
P/S
1.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.91
CTSO's EPS has soared by 53% YoY and by 26% from the previous quarter
The equity is up by 31% since the previous quarter but it has declined by 23% year-on-year
CTSO's P/B is 16% lower than its 5-year quarterly average of 4.3 and 16% lower than its last 4 quarters average of 4.3
The stock's price to sales (P/S) is 66% less than its 5-year quarterly average of 4.3 and 13% less than its last 4 quarters average of 1.7
Cytosorbents's revenue has increased by 13% YoY but it has decreased by 3% QoQ
Efficiency
How efficient is Cytosorbents business performance
The ROIC has soared by 57% YoY and by 31% from the previous quarter
CTSO's ROS has soared by 52% YoY and by 24% from the previous quarter
The ROA has increased by 43% YoY and by 25% QoQ
The ROE has grown by 18% from the previous quarter and by 13% YoY
Dividends
What is CTSO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTSO.
Financial health
How did Cytosorbents financials performed over time
The company's total assets is 40% higher than its total liabilities
CTSO's current ratio has surged by 75% year-on-year and by 19% since the previous quarter
The quick ratio has soared by 69% YoY and by 22% QoQ
The debt is 82% greater than the equity
The debt to equity has soared by 100% year-on-year but it is down by 24% since the previous quarter
The debt has surged by 54% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.